Allergan, Inc.

Allergan Sales, Inc.

Azura Ophthalmics Ltd.

Merck + Co., Inc.

Other

Allergen, Inc.

Mark Holoboski

Robert M. Burk

Mari F. Posner

Robert M Burk

David Frederick Woodward

David W Old

Yariv Donde

Michael E Garst

Mari F Posner

Todd S Gac

Danny Thang Dinh

Achim H Krauss

Steven Wade Andrews

Thang D Dinh

Jeremiah H Nguyen

Achim H-p Krauss

Jenny W Wang

June Chen

Sophie Beauchemin

Neil J Poloso

Patrick Michael Hughes

Yair Alster

Michael R Robinson

Wha-Bin Im

Wha Bin Im

Omer Rafaeli

Jinping Wan

Ke Wu

Gyorgy F Ambrus

Mark Richard Stewart

Charles Bosworth

Jie Shen

Hui Liu

Marc Gleeson

Ian Holmes

Hila Barash

Jonathan Dunn

Chandrasekar Durairaj

Tesfaye Biftu

William H Parsons

Ming Fai Chan

Mitree M Ponpipom

Robert L Bugianesi

Gregory D Berger

Narindar N Girotra

James D Bergstrom

Brent A Johnson

Michael B Roof

Lori L Whiting

Nicholas Chapman

John E Donello

Larry Allen Wheeler

Tien T Duong

Veena Viswanath

Santosh C Sinha

Ling Li

Scott M Whitcup

Richard S Graham

Vinh X Ngo

John J Acton, Iii

Yuan-Ching P Chiang

Yanbin Liang

Conrad Santini

Claude Dufresne

Sandhya Rao

Chan-Hwa Kuo

Robert W Marquis, Jr

Frederick C Beddingfield

Christopher D Hein

Mu-Lan Lee

Guang L Jiang

C H Kuo

Sandra P Plevyak

Alexander James Nicholls

Cherukury Madhu

Helen H Usansky

Mark Holobiski

Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.

Compounds and methods for the treatment of ocular disorders

Described herein are compositions and methods for the treatment or prevention of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious diseases of the anterior surface of the eye(s). Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.

Described herein are compounds, or pharmaceutically acceptable salts thereof, of the following formula:  The compounds are useful for treating inflammatory and autoimmune diseases.

3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof

Prostamide-containing biodegradable intraocular implants, prostamide compounds, prostamide-containing pharmaceutical compositions, and methods for making and using such implants and compositions for the immediate and sustained reduction of intraocular pressure and treatment of glaucoma in an eye of a patient are described.

Prostamide-containing intraocular implant

Described herein are ester prodrugs of gamma-lactam compounds of Formula (I): or pharmaceutically acceptable salt thereof, and methods of use of such compounds for the treatment of ocular diseases including, among other things, glaucoma and macular degeneration. 

Ester prodrugs of gamma-lactams and their use

Disclosed herein are methods, compounds, and compositions for fat reduction, and in particular fat reduction without significant hair growth and/or additional hair growth.

Methods for fat reduction

Disclosed herein are compounds according to Formulas 1-12, compositions comprising these compounds, and methods of lowering intraocular pressure (IOP) or causing hair growth, and methods of using the same. 

Quaternary ammonium alkyl esters as stable prodrugs

Disclosed herein are compositions comprising an amide related to a prostaglandin and a biogenic amine. Other aspects relate to certain chemical compounds, pharmaceutical compositions, and methods of treating glaucoma.

Prostamides for the treatment of glaucoma and related diseases

The invention provides ester compounds for treating ophthalmic diseases. The esters of the invention are particularly advantageous due to their stability in aqueous solutions.

Amidoalkylenyl and amidoaryl esters, compositions thereof, and methods for their use

The invention provides compositions and methods for reducing healing wounds and reducing scars and blemishes. The compositions and methods of the invention include at least one EP4 agonist set forth herein. Wounds and or scars that can be treated by the compositions and methods of the invention can arise from events such as surgery, trauma, disease, mechanical injury, burn, radiation, poisoning, and the like.

15-aryl prostaglandins as EP4 agonists, and methods of use thereof

Provided herein, inter alia, are, methods of using esters of bimatoprost with the Formula (I): 

Substituted cyclopentanes for inducing hair growth

Growing community of inventors

Laguna Beach, CA, United States of America

Robert M Burk